Quick Answer
Jazz Pharmaceuticals plc reported Total Revenue of $4.27 billion for fiscal year 2025.
Jazz Pharmaceuticals plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.27B +4.9% |
$4.07B +6.1% |
$3.83B +4.8% |
$3.66B +18.3% |
$3.09B +30.9% |
$2.36B +9.3% |
| Revenue (ASC 606) | $4.27B +4.9% |
$4.07B +6.1% |
$3.83B +4.8% |
$3.66B +18.3% |
$3.09B +30.9% |
$2.36B +9.3% |
| Net Income | -$356.15M -163.6% |
$560.12M +35.0% |
$414.83M +285.1% |
-$224.06M +32.0% |
-$329.67M -238.2% |
$238.62M -54.4% |
| Diluted EPS | -$5.84 -167.5% |
$8.65 +41.8% |
$6.10 +270.4% |
-$3.58 +35.1% |
-$5.52 -230.8% |
$4.22 -53.6% |
| Total Assets | $11.66B -2.9% |
$12.01B +5.4% |
$11.39B +5.2% |
$10.84B -11.9% |
$12.30B +88.2% |
$6.54B +18.0% |
| Cash and Equivalents | $1.39B -42.3% |
$2.41B +60.2% |
$1.51B +70.9% |
$881.48M +49.0% |
$591.45M -44.1% |
$1.06B +66.0% |
| Long-Term Debt | $4.33B -28.8% |
$6.08B +19.0% |
$5.11B -10.3% |
$5.69B -5.4% |
$6.02B +225.6% |
$1.85B +17.5% |
| Stockholders Equity | $4.32B +5.5% |
$4.09B +9.5% |
$3.74B +21.1% |
$3.09B -22.2% |
$3.97B +8.3% |
$3.66B +17.6% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$430.24M -160.0% |
$716.63M +23.9% |
$578.58M +983.0% |
-$65.53M -138.5% |
$170.28M -55.0% |
$378.07M -29.0% |
| Shares Outstanding | 61.44M +1.3% |
60.63M -2.6% |
62.26M -1.5% |
63.21M +2.6% |
61.63M +9.7% |
56.17M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.13B | +6.7% | +7.7% |
| Revenue (ASC 606) | September 30, 2025 | $1.13B | +6.7% | +7.7% |
| Net Income | September 30, 2025 | $251.41M | +16.9% | +135.0% |
| Diluted EPS | September 30, 2025 | $4.08 | +19.3% | +134.8% |
| Total Assets | September 30, 2025 | $11.36B | -7.3% | +3.8% |
| Cash and Equivalents | September 30, 2025 | $1.33B | -40.2% | +11.4% |
| Long-Term Debt | September 30, 2025 | $4.33B | -28.8% | -0.1% |
| Stockholders Equity | September 30, 2025 | $3.96B | -5.1% | +6.8% |
| R&D Expense | September 30, 2019 | $79.86M | +56.1% | +28.0% |
| Operating Income | September 30, 2025 | $57.51M | -77.9% | +108.4% |
- Jazz Pharmaceuticals plc reported Total Revenue of $4.27 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed an increase of +4.9% in Total Revenue compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Revenue (ASC 606) of $4.27 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed an increase of +4.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Net Income of -$356.15 million for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -163.6% in Net Income compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Diluted EPS of $5.84 per share (loss) for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -167.5% in Diluted EPS compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Total Assets of $11.66 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -2.9% in Total Assets compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Cash and Equivalents of $1.39 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -42.3% in Cash and Equivalents compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Long-Term Debt of $4.33 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -28.8% in Long-Term Debt compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Stockholders Equity of $4.32 billion for fiscal year 2025.
- Jazz Pharmaceuticals plc showed an increase of +5.5% in Stockholders Equity compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported R&D Expense of $299.73 million for fiscal year 2019.
- Jazz Pharmaceuticals plc showed an increase of +32.3% in R&D Expense compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Operating Income of -$430.24 million for fiscal year 2025.
- Jazz Pharmaceuticals plc showed a decrease of -160.0% in Operating Income compared to the prior fiscal year.
- Jazz Pharmaceuticals plc reported Shares Outstanding of 61.44 million shares for fiscal year 2025.
- Jazz Pharmaceuticals plc showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: